ArticleBMC medicine2025
Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSelective serotonin reuptake inhibitors (SSRIs) are frequently co-prescribed with opioids, increasing the risk of pharmacokinetic and pharmacodynamic interactions. Hydrocodone, a commonly prescribed opioid metabolized by cytochrome (CYP) 2D6 and CYP3A4, may be affected by enzyme inhibition from certain SSRIs. However, it remains unclear whether all SSRIs pose equal overdose risk or if some may be safer options for patients requiring both medications. Thus, we aimed to evaluate comparative risks of opioid overdose among patients initiating SSRIs while on hydrocodone.
methodsThis population-based cohort study utilized US public and commercial health insurance claims data from 2004 to 2022 and included patients who initiated a SSRI (citalopram, escitalopram, fluoxetine, paroxetine, or sertraline) while receiving hydrocodone treatment. The outcome was hospitalization or emergency department visit due to opioid overdose. We balanced baseline covariates via propensity score matching weights. A weighted Cox proportional hazards model compared rates across the five SSRIs.
resultsAmong 1,486,583 patients who initiated an SSRI while on hydrocodone, 403,488 (27.1%) initiated sertraline, 348,484 (23.4%) initiated citalopram, 311,375 (21.0%) initiated escitalopram, 258,957 (17.4%) initiated fluoxetine, and 164,279 (11.1%) initiated paroxetine. During a median on-treatment follow-up of 28 days, 1500 primary endpoints occurred. Weighted hazard ratios (HRs) for opioid overdose, using sertraline as the reference, were 1.21 (95% CI 1.02-1.42) for citalopram, 1.19 (1.00-1.41) for escitalopram, 1.29 (1.09-1.54) for fluoxetine, and 1.17 (0.95-1.43) for paroxetine. Using citalopram as the reference, HRs were 0.99 (0.83-1.17) for escitalopram, 1.07 (0.91-1.27) for fluoxetine, and 0.97 (0.79-1.18) for paroxetine. Relative to escitalopram, HRs were 1.09 (0.92-1.30) for fluoxetine and 0.98 (0.80-1.20) for paroxetine, and relative to fluoxetine, the HR was 0.90 (0.74-1.10) for paroxetine. Comparisons among SSRIs other than sertraline showed similar risks of overdose. Intention-to-treat analysis yielded similar findings, although the associations were attenuated.
conclusionsIn this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.